Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
Shares in Creightons PLC (LSE:CRL) dropped 10% on Wednesday despite reporting a return to profitability, as investors reacted to a cautious outlook for the year ahead. The beauty and personal care manufacturer posted a 1.6% rise in revenue to £54.1 million for the year to 31 March 2025, with strong growth in private label sales offsetting declines in branded and contract manufacturing.
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
The firm has three possible paths toward value creation at the drug development company.
The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.